Gastroesophageal Reflux Disease Treatment & Management
- Author: Marco G Patti, MD; Chief Editor: Julian Katz, MD more...
Approach Considerations
Treatment of GERD involves a stepwise approach. The goals are to control symptoms, to heal esophagitis, and to prevent recurrent esophagitis or other complications. The treatment is based on (1) lifestyle modification and (2) control of gastric acid secretion through medical therapy with antacids or PPIs or surgical treatment with corrective antireflux surgery.[5, 6, 7, 8, 9, 10]
Approximately 80% of patients have a recurrent but nonprogressive form of GERD that is controlled with medications. (See Medical Therapy.) Identifying the 20% of patients who have a progressive form of the disease is important, because they may develop severe complications, such as strictures or Barrett esophagus. For patients who develop complications, surgical treatment should be considered at an earlier stage to avoid the sequelae of the disease that can have serious consequences. (See Surgical Therapy.)
Lifestyle Modifications
Lifestyle modifications include the following:
- Losing weight (if overweight)
- Avoiding alcohol, chocolate, citrus juice, and tomato-based products (The ACG 2005 guidelines also suggest avoiding peppermint, coffee, and possibly the onion family as well.[24] )
- Avoiding large meals
- Waiting 3 hours after a meal before lying down
- Elevating the head of the bed 8 inches
According to the ACG 2005 guidelines, studies have shown decreased distal esophageal acid exposure after these changes are made, but little data are available to confirm these findings.[24]
Lifestyle modifications are the first line of management in pregnant women with GERD. Advise patients to elevate the head of the bed; avoid bending or stooping positions; eat small, frequent meals; and refrain from ingesting food (except liquids) within 3 hours of bedtime.
Pharmacologic Therapy
Antacids
Antacids were the standard treatment in the 1970s and are still effective in controlling mild symptoms of GERD. Antacids should be taken after each meal and at bedtime.
H2 receptor antagonists and H2 blocker therapy
H2 receptor antagonists are the first-line agents for patients with mild to moderate symptoms and grades I-II esophagitis. Options include ranitidine (Zantac), cimetidine (Tagamet), famotidine (Pepcid), and nizatidine (Axid).
H2 receptor antagonists are effective for healing only mild esophagitis in 70-80% of patients with GERD and for providing maintenance therapy to prevent relapse. Tachyphylaxis has been observed, suggesting that pharmacologic tolerance can reduce the long-term efficacy of these drugs.
Additional H2 blocker therapy has been reported to be useful in patients with severe disease (particularly those with Barrett esophagus) who have nocturnal acid breakthrough.
Proton pump inhibitors
PPIs are the most powerful medications available for treating GERD. These agents should be used only when this condition has been objectively documented. They have few adverse effects and are well tolerated for long-term use. However, data have shown that PPIs can interfere with calcium homeostasis and aggravate cardiac conduction defects. These agents have also been responsible for hip fracture in postmenopausal women.[27] Options include omeprazole (Prilosec), lansoprazole (Prevacid), rabeprazole (Aciphex), and esomeprazole (Nexium). A research review by the Agency for Healthcare Research and Quality (AHRQ) concluded, on the basis of grade A evidence, that PPIs were superior to H2 receptor antagonists for the resolution of GERD symptoms at 4 weeks and healing of esophagitis at 8 weeks.[28]
In addition, the AHRQ found no difference between individual PPIs (omeprazole, lansoprazole, pantoprazole, and rabeprazole) for relief of symptoms at 8 weeks. For symptom relief at 4 weeks, esomeprazole 20 mg was equivalent, but esomeprazole 40 mg superior, to omeprazole 20 mg.[28]
The LOTUS trial, a 5-year exploratory randomized, open, parallel-group trial demonstrated that with antireflux therapy for GERD, either using drug-induced acid suppression with esomeprazole or laparoscopic antireflux surgery, most patients achieve and remain in remission at 5 years.[29]
Prokinetic medications and reflux inhibitors
Prokinetic agents are somewhat effective but only in patients with mild symptoms; other patients usually require additional acid-suppressing medications, such as PPIs. The usual regimen in adults is metoclopramide, 10 mg/day orally. Long-term use of prokinetic agents may have serious, even potentially fatal, complications and should be discouraged.
Indications for Surgical Treatment
As in many other fields, surgical therapy for gastroesophageal reflux has evolved a great deal. A few historical procedures of note include the Allison crural repair, the Boerema anterior gastropexy, and the Angelchik prosthesis. Both the Allison and the Boerema repairs have high failure rates and are rarely, if ever, used.[30, 31] The Angelchik prosthesis is a silicone ring that is positioned at the gastroesophageal junction and prevents reflux. The Angelchik prosthesis was rarely used in children and has been largely abandoned because of a high rate of complications.[32]
Today, both transthoracic and transabdominal fundoplications are performed, including partial (anterior or posterior) and circumferential wraps. The most commonly performed operation today in both children and adults is the Nissen fundoplication, which is a 360° transabdominal fundoplication (see the image below).[33, 34] First reported in 1991, laparoscopic fundoplication is well studied in adult populations. Laparoscopic fundoplication has also quickly gained acceptance for use in children.[35, 36, 37, 38, 39, 40]
Nissen fundoplication. Indications for fundoplication include the following:
- Patients with symptoms that are not completely controlled by PPI therapy can be considered for surgery; surgery can also be considered in patients with well-controlled GERD who desire definitive, one-time treatment
- The presence of Barrett esophagus is an indication for surgery (whether acid suppression improves the outcome or prevents the progression of Barrett esophagus remains unknown, but most authorities recommend complete acid suppression in patients with histologically proven Barrett esophagus)
- The presence of extraesophageal manifestations of GERD may indicate the need for surgery; these include the following: (1) respiratory manifestations (eg, cough, wheezing, aspiration); (2) ear, nose, and throat manifestations (eg, hoarseness, sore throat, otitis media); and (3) dental manifestations (eg, enamel erosion)
- Young patients
- Poor patient compliance with regard to medications
- Postmenopausal women with osteoporosis
- Patients with cardiac conduction defects
- Cost of medical therapy
Several randomized clinical trials have challenged the benefits of surgery in controlling GERD. Lundell followed up his cohort of patients for 5 years and did not find surgery to be superior to PPI therapy.[41] Spechler found that, at 10 years after surgery, 62% of patients were back on antireflux medications.[42] A very rigorous, randomized study by Anvari et al reestablished surgery as the criterion standard in treating GERD.[43] The investigators showed that, at 1 year, the outcome and the symptom control in the surgical group was better than that in the medical group.[43]
A British multicenter randomized study conducted by Grant et al also compared surgical treatment versus medical therapy in patients with documented evidence of GERD.[44] The type of laparoscopic fundoplication was decided by the respective surgeons. Individuals who had received medication for their condition had taken them for a median of 32 months before participating in the study. The investigators reported that by 12 months, 38% of those who had undergone surgery were taking reflux medication, compared with 90% of the individuals randomized to medical management.[44]
Long-term results of laparoscopic antireflux surgery have shown that, at 10 years, 90% of patients are symptom free and only a minority still take PPIs.[45]
Laparoscopic fundoplication
Laparoscopic fundoplication is performed under general endotracheal anesthesia. Five small (5-mm to 10-mm) incisions are used (see image below). The fundus of the stomach is wrapped around the esophagus to create a new valve at the level of the esophagogastric junction.
Laparoscopic Nissen fundoplication. The essential elements of the operation are as follows:
- Complete mobilization of the fundus of the stomach with division of the short gastric vessels
- Reduction of the hiatal hernia
- Narrowing of the esophageal hiatus
- Creation of a 360° fundoplication over a large intraesophageal dilator (Nissen fundoplication)
Laparoscopic fundoplication lasts 2-2.5 hours. The hospital stay is approximately 2 days. Patients resume regular activities within 2-3 weeks. Approximately 92% of patients obtain resolution of symptoms after undergoing laparoscopic fundoplication.
The AHRQ found, on the basis of limited evidence, that laparoscopic fundoplication was as effective as open fundoplication for relieving heartburn and regurgitation, improving quality of life, and decreasing use of antisecretory medications.[28]
Although a prospective, randomized trial has never been performed to compare PPIs to laparoscopic fundoplication, the authors believe fundoplication is preferable for the following reasons:
- PPIs, although effective in controlling the acid component of the refluxate, do not eliminate the reflux of bile, which some believe to be a major contributor to the pathogenesis of Barrett epithelium
- Patients with Barrett esophagus tend to have lower LES pressure and worse esophageal peristalsis than patients without Barrett esophagus; patients with Barrett esophagus are also exposed to a larger amount of reflux
- A fundoplication offers the only possibility of stopping any kind of reflux by creating a competent LES; however, until the definitive answer is known, the authors recommend that patients with Barrett esophagus continue to undergo periodic endoscopic surveillance even after laparoscopic fundoplication
Gallup Organization. Heartburn Across America: A Gallup Organization National Survey. Princeton, NJ: Gallup Organization.; 1988.
Richter JE. Surgery for reflux disease: reflections of a gastroenterologist. N Engl J Med. Mar 19 1992;326(12):825-7. [Medline].
Chen CL, Robert JJ, Orr WC. Sleep symptoms and gastroesophageal reflux. J Clin Gastroenterol. Jan 2008;42(1):13-7. [Medline].
Sveen S. Symptom check: is it GERD?. J Contin Educ Nurs. Mar 2009;40(3):103-4. [Medline].
Giannini EG, Zentilin P, Dulbecco P, Vigneri S, Scarlata P, Savarino V. Management strategy for patients with gastroesophageal reflux disease: a comparison between empirical treatment with esomeprazole and endoscopy-oriented treatment. Am J Gastroenterol. Feb 2008;103(2):267-75. [Medline].
Katz PO. Medical therapy for gastroesophageal reflux disease in 2007. Rev Gastroenterol Disord. Fall 2007;7(4):193-203. [Medline].
Fass R, Sifrim D. Management of heartburn not responding to proton pump inhibitors. Gut. Feb 2009;58(2):295-309. [Medline].
Fass R. Proton pump inhibitor failure--what are the therapeutic options?. Am J Gastroenterol. Mar 2009;104 Suppl 2:S33-8. [Medline].
Heidelbaugh JJ, Goldberg KL, Inadomi JM. Overutilization of proton pump inhibitors: a review of cost-effectiveness and risk [corrected]. Am J Gastroenterol. Mar 2009;104 Suppl 2:S27-32. [Medline].
Dial MS. Proton pump inhibitor use and enteric infections. Am J Gastroenterol. Mar 2009;104 Suppl 2:S10-6. [Medline].
Mittal RK, Rochester DF, McCallum RW. Sphincteric action of the diaphragm during a relaxed lower esophageal sphincter in humans. Am J Physiol. Jan 1989;256(1 Pt 1):G139-44. [Medline].
Mittal RK, McCallum RW. Characteristics of transient lower esophageal sphincter relaxation in humans. Am J Physiol. May 1987;252(5 Pt 1):G636-41. [Medline].
Mittal RK, Rochester DF, McCallum RW. Effect of the diaphragmatic contraction on lower oesophageal sphincter pressure in man. Gut. Dec 1987;28(12):1564-8. [Medline]. [Full Text].
Stein HJ, DeMeester TR. Outpatient physiologic testing and surgical management of foregut motility disorders. Curr Probl Surg. Jul 1992;29(7):413-555. [Medline].
Kahrilas PJ, Dodds WJ, Hogan WJ, Kern M, Arndorfer RC, Reece A. Esophageal peristaltic dysfunction in peptic esophagitis. Gastroenterology. Oct 1986;91(4):897-904. [Medline].
Buttar NS, Falk GW. Pathogenesis of gastroesophageal reflux and Barrett esophagus. Mayo Clin Proc. Feb 2001;76(2):226-34. [Medline].
[Best Evidence] Hampel H, Abraham NS, El-Serag HB. Meta-analysis: obesity and the risk for gastroesophageal reflux disease and its complications. Ann Intern Med. Aug 2 2005;143(3):199-211. [Medline]. [Full Text].
Herbella FA, Sweet MP, Tedesco P, Nipomnick I, Patti MG. Gastroesophageal reflux disease and obesity. Pathophysiology and implications for treatment. J Gastrointest Surg. Mar 2007;11(3):286-90. [Medline].
Merrouche M, Sabaté JM, Jouet P, Harnois F, Scaringi S, Coffin B, et al. Gastro-esophageal reflux and esophageal motility disorders in morbidly obese patients before and after bariatric surgery. Obes Surg. Jul 2007;17(7):894-900. [Medline].
Murray L, Johnston B, Lane A, Harvey I, Donovan J, Nair P, et al. Relationship between body mass and gastro-oesophageal reflux symptoms: The Bristol Helicobacter Project. Int J Epidemiol. Aug 2003;32(4):645-50. [Medline]. [Full Text].
Pandolfino JE, El-Serag HB, Zhang Q, Shah N, Ghosh SK, Kahrilas PJ. Obesity: a challenge to esophagogastric junction integrity. Gastroenterology. Mar 2006;130(3):639-49. [Medline].
El-Serag HB, Graham DY, Satia JA, Rabeneck L. Obesity is an independent risk factor for GERD symptoms and erosive esophagitis. Am J Gastroenterol. Jun 2005;100(6):1243-50. [Medline].
Tutuian R,. Adverse effects of drugs on the esophagus. Best Pract Res Clin Gastroenterol. Apr 2010;24(2):91-7. [Medline].
DeVault KR, Castell DO. Updated guidelines for the diagnosis and treatment of gastroesophageal reflux disease. Am J Gastroenterol. Jan 2005;100(1):190-200. [Medline].
Bhatia J, Parish A. GERD or not GERD: the fussy infant. J Perinatol. May 2009;29 Suppl 2:S7-11. [Medline].
Levine MS, Rubesin SE. Diseases of the esophagus: diagnosis with esophagography. Radiology. Nov 2005;237(2):414-27. [Medline].
Yang YX, Lewis JD, Epstein S, Metz DC. Long-term proton pump inhibitor therapy and risk of hip fracture. JAMA. Dec 27 2006;296(24):2947-53. [Medline]. [Full Text].
Agency for Healthcare Research and Quality. Comparative Effectiveness of Management Strategies for Gastroesophageal Reflux Disease - Executive Summary. AHRQ pub. no. 06-EHC003-1. December 2005. Available at http://effectivehealthcare.ahrq.gov/healthInfo.cfm?infotype=rr&ProcessID=1&DocID=42. Accessed September 27, 2010.
Galmiche JP, Hatlebakk J, Attwood S, et al. Laparoscopic antireflux surgery vs esomeprazole treatment for chronic GERD: the LOTUS randomized clinical trial. JAMA. May 18 2011;305(19):1969-77. [Medline].
Boerema I. Hiatus hernia: repair by right-sided, subhepatic, anterior gastropexy. Surgery. Jun 1969;65(6):884-93. [Medline].
Allison PR. Hiatus hernia: (a 20-year retrospective survey). Ann Surg. Sep 1973;178(3):273-6. [Medline]. [Full Text].
Varshney S, Kelly JJ, Branagan G, Somers SS, Kelly JM. Angelchik prosthesis revisited. World J Surg. Jan 2002;26(1):129-33. [Medline].
Nissen R, Rossetti M, Siewert R. [20 years in the management of reflux disease using fundoplication]. Chirurg. Oct 1977;48(10):634-9. [Medline].
Kazerooni NL, VanCamp J, Hirschl RB, Drongowski RA, Coran AG. Fundoplication in 160 children under 2 years of age. J Pediatr Surg. May 1994;29(5):677-81. [Medline].
Dallemagne B, Weerts JM, Jehaes C, Markiewicz S, Lombard R. Laparoscopic Nissen fundoplication: preliminary report. Surg Laparosc Endosc. Sep 1991;1(3):138-43. [Medline].
Nilsson G, Larsson S, Johnsson F. Randomized clinical trial of laparoscopic versus open fundoplication: blind evaluation of recovery and discharge period. Br J Surg. Jul 2000;87(7):873-8. [Medline].
Wenner J, Nilsson G, Oberg S, Melin T, Larsson S, Johnsson F. Short-term outcome after laparoscopic and open 360 degrees fundoplication. A prospective randomized trial. Surg Endosc. Oct 2001;15(10):1124-8. [Medline].
Somme S, Rodriguez JA, Kirsch DG, Liu DC. Laparoscopic versus open fundoplication in infants. Surg Endosc. Jan 2002;16(1):54-6. [Medline].
Rangel SJ, Henry MC, Brindle M, Moss RL. Small evidence for small incisions: pediatric laparoscopy and the need for more rigorous evaluation of novel surgical therapies. J Pediatr Surg. Oct 2003;38(10):1429-33. [Medline].
Rothenberg SS. The first decade's experience with laparoscopic Nissen fundoplication in infants and children. J Pediatr Surg. Jan 2005;40(1):142-6; discussion 147. [Medline].
Lundell L, Miettinen P, Myrvold HE, Pedersen SA, Liedman B, Hatlebakk JG, et al. Continued (5-year) followup of a randomized clinical study comparing antireflux surgery and omeprazole in gastroesophageal reflux disease. J Am Coll Surg. Feb 2001;192(2):172-9; discussion 179-81. [Medline].
Spechler SJ. Epidemiology and natural history of gastro-oesophageal reflux disease. Digestion. 1992;51 Suppl 1:24-9. [Medline].
Anvari M, Allen C, Marshall J, Armstrong D, Goeree R, Ungar W, et al. A randomized controlled trial of laparoscopic nissen fundoplication versus proton pump inhibitors for treatment of patients with chronic gastroesophageal reflux disease: One-year follow-up. Surg Innov. Dec 2006;13(4):238-49. [Medline].
[Best Evidence] Grant AM, Wileman SM, Ramsay CR, Mowat NA, Krukowski ZH, Heading RC, et al. Minimal access surgery compared with medical management for chronic gastro-oesophageal reflux disease: UK collaborative randomised trial. BMJ. Dec 15 2008;337:a2664. [Medline]. [Full Text].
El-Serag HB. Time trends of gastroesophageal reflux disease: a systematic review. Clin Gastroenterol Hepatol. Jan 2007;5(1):17-26. [Medline].
Mattioli S, Lugaresi ML, Di Simone MP, D'Ovidio F, Pilotti V, Bassi F, et al. The surgical treatment of the intrathoracic migration of the gastro-oesophageal junction and of short oesophagus in gastro-oesophageal reflux disease. Eur J Cardiothorac Surg. Jun 2004;25(6):1079-88. [Medline].
Scheffer RC, Samsom M, Haverkamp A, Oors J, Hebbard GS, Gooszen HG. Impaired bolus transit across the esophagogastric junction in postfundoplication dysphagia. Am J Gastroenterol. Aug 2005;100(8):1677-84. [Medline].

